story of the week
ASCO 2020: Pembrolizumab Offers Better Outcomes Than Chemotherapy for High Microsatellite Instability Metastatic Colorectal Carcinoma
Pembrolizumab should become the new standard of care for these patients, says study author
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles: